| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Cosmos Health Inc.$0.28
0 (0%)
Market Cap
13.74 M
EPS
-0.65
P/E Ratio
-
Value Trade
399.70 K
SEC Financials
Q1 2026Dilution Risk
Revenue
17.93 M
R&D Expenses
-
Operating CF
-1.07 M
Total Assets
62.37 M
Total Liabilities
42.54 M
Equity
19.83 M
D/E Ratio
12,345
-17.59 %
Week
-26 %
1 Month
-34.47 %
3 Month
-60.17 %
6 Month
-99.81 %
5 Year
-99.92 %
All Time
Cash Data
Cash Position
2.16 M
Monthly Burn
356.00 K
Runway
4.4 mo
Burn Trend
SEC Filing
May 20, 2026
Overview
Volume
3.39 M
52 Week Range
0.25 - 1.32
% held by Insiders
32.85 %
% held by Institutions
2.37 %
Enterprise Value
30.03 M
Total Shares
59.97 M
Short %
11.38 %
Float Shares
44.38 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Cosmos Health Inc.
2Total events
1Upcoming
0Tier-1 (high impact)
2026 – 2026Coverage
Upcoming catalysts 1
TBD
T2ATM Program
Subscribe to view catalyst details
Event history 1
TBD
▲ATM ProgramCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in COSM
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
COSM Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
COSMCosmos Health Share Buyback Surpasses $1 Million, Reaching 4.84 Million Shares; Continues Open Market Repurchases
Cosmos Health Inc. has successfully repurchased an additional 250,000 shares, bringing the total to approximately 4.84 million shares for around $1.04 million. The company is committed to continuing its share repurchase program, which may extend beyond its current expiration date of December 31, 2026. CEO Greg Siokas emphasized the importance of this milestone in their capital allocation strategy.
Read more →COSMCosmos Health Share Buyback Surpasses 4.5 Million Shares; Continues Open Market Repurchases
Cosmos Health Inc. has successfully repurchased a total of 4,588,000 shares under its share repurchase program, spending approximately $970,000. The program, which allows for up to $5 million in repurchases, is set to continue until December 31, 2026. CEO Greg Siokas highlighted the company's commitment to enhancing shareholder value through these repurchases.
Read more →COSM▲ +5.1%on this newsshared move
Cosmos Health Share Buyback Expands to 4.49 Million Shares; Continues Open Market Repurchases
Cosmos Health Inc. has repurchased an additional 133,000 shares, bringing the total to approximately 4.49 million shares under its $5 million repurchase program. The company aims to continue these repurchases, contingent on market conditions. CEO Greg Siokas expressed confidence in the company's growth prospects and believes the shares are undervalued.
Read more →COSMCosmos Health Share Buyback Reaches 4.36 Million Shares; Continues Open Market Repurchases
Cosmos Health Inc. has successfully repurchased 4.36 million shares under its $5 million buyback program, with the latest purchase of 215,000 shares at approximately $0.325 each. The company plans to continue repurchases until the program's expiration on December 31, 2026, depending on market conditions. CEO Greg Siokas emphasized the company's belief that its shares are undervalued.
Read more →COSMCosmos Health Accelerates Prescription Medicine Strategy with Libytec Partnership to Commercialize DIABIT-IS X in Greece
Cosmos Health has partnered with Libytec Pharmaceutical S.A. to commercialize its type-2 diabetes medication, DIABIT-IS X, in Greece. Under the five-year agreement, Cosmos will supply the medication while Libytec manages distribution and promotion. This collaboration aims to enhance revenue and cash flow visibility, leveraging Greece's national health insurance system for broader patient access.
Read more →COSM▲ +15.8%on this newsshared move
Cosmos Health Launches Subscription Model
Cosmos Health has launched a subscription model for its NOOR Collagen product in the U.S., achieving a repeat purchase rate above 60% and margins over 50%. The company aims to enhance customer loyalty and predictability in cash flow through this model. Plans are in place to extend the subscription service to additional products globally.
Read more →COSMCosmos Health Expands Share Buyback to 4.14 Million Shares; Continues Open Market Repurchases
Cosmos Health Inc. has expanded its share buyback program, repurchasing an additional 80,000 shares, bringing the total to 4.14 million shares. The company believes its shares are undervalued and intends to continue repurchases until the program expires on December 31, 2026. CEO Greg Siokas emphasizes the commitment to enhancing shareholder value.
Read more →COSM▲ +6.1%on this news· ran to +24% by day 3shared move
Cosmos Health Share Buyback Surpasses 4 Million Shares; Continues Open Market Repurchases
Cosmos Health Inc. has successfully repurchased 4,060,000 shares of its common stock, totaling approximately $811,000 under its share repurchase program. The company plans to continue these repurchases until the program's expiration on December 31, 2026. CEO Greg Siokas emphasized the belief that the stock is undervalued, reinforcing their commitment to enhancing shareholder value.
Read more →COSMCosmos Health Share Buyback Expands to 3.87 Million Shares; Continues Open Market Repurchases
Cosmos Health Inc. has repurchased an additional 230,000 shares, bringing the total to 3.87 million under its $5 million buyback program. The company plans to continue repurchases until the program's expiration on December 31, 2026. CEO Greg Siokas emphasized the belief that the market undervalues the company's potential.
Read more →COSMCosmos Health Reports Preliminary Record Q2 and H1 2026 Revenue, Up Over 30% Year-Over-Year; Continues Open Market Share Repurchases
Cosmos Health Inc. reported record revenues for Q2 and H1 2026, with a 31.5% increase year-over-year for Q2, totaling approximately $19.4 million. The first half of 2026 also saw a revenue increase of 31%, reaching about $37.3 million. The company is actively repurchasing shares under a $5 million buyback program, signaling confidence in its market position.
Read more →COSM▲ +5.2%on this newsshared move
Cosmos Health Share Buyback Increases to 3.64 Million Shares; Continues Open Market Purchases
Cosmos Health Inc. has increased its share buyback program, repurchasing an additional 220,000 shares at an average price of $0.2229. This brings the total repurchased shares to 3.64 million, with a commitment to continue open market purchases until the program's expiration on December 31, 2026. CEO Greg Siokas expressed confidence in the company's undervaluation and the effectiveness of returning capital to shareholders.
Read more →COSMCosmos Health Expands Buyback to 3.42 Million Shares With Additional 770,000-Share Repurchase; Continues Open Market Purchases
Cosmos Health Inc. has expanded its share repurchase program, acquiring an additional 770,000 shares, bringing the total to 3.42 million shares repurchased for about $650,000. The program, which may continue until December 31, 2026, reflects the company's belief in the intrinsic value of its shares. CEO Greg Siokas emphasized the attractiveness of this capital allocation for shareholders.
Read more →COSM▲ +7.9%on this news· ran to +37% by day 3shared move
Cosmos Health Completes Initial Repurchase of 2.65 Million Shares for $500,000; Continues Open Market Buybacks at Current Pace
Cosmos Health Inc. has completed the repurchase of 2.65 million shares for $500,000, as part of a $5 million buyback program initiated on June 30, 2026. The company plans to continue these open market purchases until December 31, 2026, depending on market conditions. CEO Greg Siokas emphasized the company's belief that its shares are undervalued and that repurchasing stock is a strategic investment.
Read more →COSM▲ +13.2%on this news· ran to +65% by day 3shared move
Cosmos Health Authorizes Up to $5 Million Share Repurchase Program
Cosmos Health Inc. has authorized a share repurchase program of up to $5 million. The program aims to buy back shares in the open market or through private transactions, depending on market conditions. CEO Greg Siokas highlighted the company's strong fundamentals and growth potential, citing record revenue and expanding operations. The program is set to expire on December 31, 2026.
Read more →COSM▼ -5.9%on this newsshared move
Cosmos Health Signs Distribution Agreement With IMC, Owner of Qatar's Largest Pharmacy Chain; Secures Initial Purchase Order of 31,000 Sky Premium Life Units
Cosmos Health Inc. has signed a distribution agreement with International Medical Company (IMC) to enhance its presence in Qatar with its Sky Premium Life line of nutraceuticals. IMC has placed an initial order for 31,000 units, indicating strong market interest. This partnership is expected to facilitate Cosmos Health's growth in the Gulf region.
Read more →COSMCosmos Health Advances International Patent Application for Its Proprietary Hydrogel Weight Management Platform Across the U.S., Europe, Australia, and Canada
Cosmos Health has advanced its international patent application for the proprietary hydrogel technology aimed at body weight management across major markets including the U.S., Europe, Australia, and Canada. This move follows the acquisition of the CCX0722 intellectual property, allowing the company to fully own the technology without third-party dependencies. The hydrogel is designed to aid in weight management by promoting satiety, and the global weight management market is expected to grow significantly in the coming years.
Read more →COSM▲ +6.1%on this newsshared move
Cosmos Health’s C-Sept PRO Gains Strong Traction Across Leading Greek Public and Private Hospital Groups, With Annualized Sales Poised to Exceed $1.3 Million at Approximately 72% Gross Margin
Cosmos Health Inc. has reported significant sales growth for its antiseptic solution, C-Sept PRO, achieving average monthly sales of over $93,000. This growth is expected to lead to annualized sales exceeding $1.3 million, with a gross margin of around 72%. The product's adoption in Greek hospitals highlights its effectiveness and potential for expansion into other European markets.
Read more →COSMCosmos Health Signs Agreement to Deploy Artificial Intelligence (AI)-Powered Call Center to Optimize Order Intake, Customer Communications, and Operating Efficiency
Cosmos Health Inc. has signed an agreement to implement an AI-powered call center through its subsidiary, CosmoFarm S.A. This initiative is part of the company's broader strategy to integrate AI across its operations, aiming to enhance customer communications and optimize order intake. The AI platform is expected to improve efficiency and reduce operational costs significantly.
Read more →COSMCosmos Health Builds Contract Manufacturing Orderbook to Over 25 Million Units; Division Positioned to Generate Over $10 Million in Recurring Annual Profit
Cosmos Health Inc. has announced that its subsidiary, Cana Laboratories, has secured a cumulative orderbook exceeding 25 million units through multi-year agreements. This development positions the contract manufacturing division to generate over $10 million in recurring annual profit. The orders span various therapeutic categories, reducing reliance on any single product or partner, and are produced at a newly upgraded EU-GMP-licensed facility in Athens.
Read more →COSM▲ +9.9%on this newsshared move
CosmoFarm Delivers Record Q2 2026 Revenue of Over $15M, Representing $60+ Million Annualized Run-Rate; Adds Over 80 Pharmacies and Expands AI Automation and Facility Capacity
Cosmos Health Inc. reported a record revenue of over $15 million for Q2 2026, indicating a strong annualized run-rate of over $60 million. The company's subsidiary, CosmoFarm, expanded its distribution network by adding more than 80 pharmacies. To support this growth, Cosmos Health is investing in AI automation and expanding its facility capacity.
Read more →COSMCosmos Health Enters the $163 Billion Global Skincare Market; Sales Already Underway in the United States
Cosmos Health Inc. has entered the global skincare market with a new collagen-based skincare line, which has already begun sales in the U.S. The company aims to diversify its portfolio and capitalize on the high-growth skincare segment, projected to reach $203 billion by 2033. CEO Greg Siok highlighted the strategic importance of this move for the company's growth.
Read more →COSMCosmos Health Signs 2.86 Million-Unit Contract Manufacturing Agreement With Pharmex S.A. Across Three Dermatological Products
Cosmos Health Inc. has announced a five-year contract manufacturing agreement with Pharmex S.A. to produce three dermatological products, totaling approximately 2.86 million units. This partnership aims to enhance Cosmos Health's manufacturing capabilities and strengthen its role in contract manufacturing. The agreement reflects the trust in Cana Laboratories' production capabilities and is expected to generate stable, recurring revenue.
Read more →COSM▲ +12.9%on this newsshared move
Cosmos Health Provides Update on United States Portfolio; Four 18 Series Products Introduced With Projected Annualized Revenue Over $22.7M and Approximately $17.0M Gross Profit
Cosmos Health Inc. has launched its 18 Series nutraceutical products in the U.S., projecting over $22.7 million in annual revenue and around $17 million in gross profit. The company reports strong early demand and aims to expand its product portfolio to 18 items. CEO Greg Siokas emphasizes the focus on profitability and future growth.
Read more →COSMCosmos Health Receives New Contract Manufacturing Orders Totaling 253,657 Units Across a Range of Medicines
Cosmos Health Inc. announced that its subsidiary, Cana Laboratories, has secured new contract manufacturing orders totaling 253,657 units for various pharmaceutical products. The orders highlight the growing demand for Cana's manufacturing capabilities and the company's commitment to building a diversified business. CEO Greg Siokas noted the importance of these partnerships for long-term shareholder value.
Read more →COSMCosmos Health Reports Annualized Sales Exceeding $1.5M for Its C-Scrub and C-Sept Antiseptic Brands in the UK and Greece; Plans EU Expansion Targeting $7.4M in Revenue and $5.3M in Gross Profit
Cosmos Health reported annualized sales exceeding $1.5 million for its antiseptic brands, C-Scrub and C-Sept, in the UK and Greece. The company plans to expand into the EU, targeting $7.4 million in revenue and $5.3 million in gross profit over the next three years. With gross margins above 70%, these products are becoming key components of Cosmos Health's portfolio.
Read more →COSMCosmos Health Signs LOI to Acquire Doc Pharma S.A., a European GMP Pharmaceutical Manufacturer, a Transformative Step Expected to Boost Assets, Profitability, Production Capacity, and Product Portfolio
Cosmos Health has signed a letter of intent to acquire Doc Pharma S.A., a GMP-certified pharmaceutical manufacturer. The acquisition aims to enhance Cosmos Health's asset base, profitability, and production capacity. With a state-of-the-art facility and a diverse product portfolio, the deal is expected to support margin expansion and cash flow. The transaction will undergo independent review and is subject to shareholder approval.
Read more →COSMCosmos Health Secures Additional 180-Day Nasdaq Extension to Regain Bid Price Compliance
Cosmos Health Inc. has received a 180-day extension from Nasdaq to meet the minimum bid price requirement of $1.00 per share, now due by December 7, 2026. The company is compliant with other listing requirements and aims to enhance shareholder value without resorting to a reverse stock split unless absolutely necessary. CEO Greg Siokas emphasized the company's commitment to executing its business strategy to regain compliance.
Read more →COSMCosmos Health Signs 3-Year Contract Manufacturing Agreement with Verisfield for 3.9 Million Units of VASCLOR GEST Progesterone Pessaries
Cosmos Health Inc. has announced a three-year contract manufacturing agreement with Verisfield S.A. for the production of 3.9 million units of VASCLOR GEST progesterone pessaries. This partnership aims to enhance women's health and reproductive medicine. The agreement is expected to broaden Cana Laboratories' customer base and contribute to the growth of its contract manufacturing segment.
Read more →COSMCosmos Health CEO Issues Letter to Shareholders: Building an Innovative AI-Driven Global Healthcare Platform — Record Growth with U.S. Expansion Underway
Cosmos Health Inc. reported record revenue of $65.3 million for FY2025 and a strong start to Q1 2026. The company is actively expanding into the U.S. market and targeting over $200 million in revenue by 2029. CEO Greg Siokas addressed shareholders, emphasizing the company's commitment to growth and innovation while acknowledging recent share price declines.
Read more →COSMCosmos Health Inaugurates State-of-the-Art Capsule Production Line with New 5-Year Contract Manufacturing Agreement with Provident Pharmaceuticals for 385,000 Units of CERTORUN
Cosmos Health Inc. has inaugurated a new capsule production line through its subsidiary, Cana Laboratories. This facility will manufacture 385,000 units of the antidepressant CERTORUN over a five-year contract with Provident Pharmaceuticals. The production will enhance the company's revenue and strengthen its manufacturing capabilities. CEO Greg Siokas emphasized the importance of this agreement for long-term growth.
Read more →COSMCosmos Health Provides Balance Sheet Update: Highlights European Investment Bank Financing Discussions for up to €25M, Eliminates 38% of Warrant Overhang with No Dilution; Reaffirms Growth Trajectory; Notes No Known Business Reason for Recent Share Price Decline
Cosmos Health Inc. has reported a positive balance sheet update, highlighting a decrease in total liabilities and an increase in stockholders' equity. The company is in discussions with the European Investment Bank for financing of up to €25 million and has eliminated a significant portion of its warrant overhang without dilution. Despite these advancements, the company noted a recent decline in its share price without a clear business reason.
Read more →COSM▼ -10.2%on this news
Cosmos Health Reports Q1 2026 Results: Revenue Up 31% to $17.9M, New Q1 Record; Total Liabilities Reduced by $4.5M; Stockholders' Equity Up 7.6%; Cash of $2.2M; Record Momentum Continues into Q2 with U.S. Expansion Under
Cosmos Health (COSM) reported Q1 2026 results with revenue rising 31% to a record $17.9 million, driven by strong performance across their core segments. The company reduced total liabilities by $4.5 million and increased stockholders' equity by 7.6%. Despite these positive indicators, adjusted EBITDA remains near breakeven, highlighting challenges due to strategic investment costs. The company noted continued growth momentum as it actively expands into the U.S. market.
Read more →COSM▲ +16.9%on this news
Cosmos Health Reports Full Year 2025 Results: Revenue Hits All-Time Record of $65.3M, Up 20%; Gross Profit Surges 83% to $7.9M; Gross Margin Expands 418 Basis Points; Adjusted EPS Improves 82%; Cash Position Up 10x to $3
Cosmos Health reported record financial results for the full year 2025, achieving a revenue of $65.3 million, representing a 20% increase compared to 2024. The gross profit surged by 83% to $7.9 million, while the gross margin expanded significantly. Key initiatives included securing long-term agreements in contract manufacturing and expanding their product portfolio globally. The company maintained a robust cash position and continued to advance its research and development pipeline.
Read more →COSM▼ -8.3%on this news
Cosmos Health Announces Accelerating Customer Growth, Improving Unit Economics and Robotic Expansion Supporting $40M in Additional Annual Revenue
Cosmos Health Inc. reported significant growth in its pharmaceutical distribution subsidiary, Cosmofarm, with a 20% increase in active customers and improved unit economics. The company is expanding its delivery routes and investing in automation to enhance service quality and capacity. Management anticipates continued growth in 2026, supported by a $1 million investment in robotic infrastructure.
Read more →COSMCosmos Health Announces Initiation of Analyst Coverage with $4.50 Valuation by Zacks Small-Cap Research
Cosmos Health Inc. announced that Zacks Small-Cap Research has initiated coverage with a valuation of $4.50 per share. The report highlights the company's diversified revenue base, vertical integration, and strong revenue growth outlook, projecting revenues to reach $98.6 million in 2026. Additionally, Cosmos Health's expansion into the U.S. market and advancements in its R&D pipeline were emphasized as key growth drivers.
Read more →COSMCosmos Health Enters Manufacturing Agreement with Libytec for PathMuscle Medicine, with Five-Year Volumes Expected to Exceed 1.2 Million Units
Cosmos Health Inc. has announced a manufacturing agreement with Libytec Pharmaceutical S.A. for the production of PathMuscle, a muscle relaxant and analgesic combination. The agreement includes a commitment to produce over 1.2 million units over five years, enhancing Cosmos Health's manufacturing capacity and market presence in Greece. CEO Greg Siokas emphasized the strategic importance of this collaboration for the company's growth.
Read more →COSMCosmos Health Reports Record Q3 2025 Results with All-Time High Revenue, Gross Profit and Gross Margin; Revenue Up 38% to $17.1M, Gross Profit Up 116% to $2.6M, Adjusted EBITDA Up 74%, Cash Position Up to $4.63M from $0.
Cosmos Health reported record Q3 results for 2025, achieving an all-time high revenue of $17.1 million, marking a 38% increase from the previous year. The company's gross profit surged 116% to $2.6 million, with significant contributions from various business segments, including contract manufacturing and distribution. Despite these gains, the company faced a net loss of $5.35 million due to non-cash charges, while its cash position improved to $4.63 million. Looking ahead, Cosmos Health aims to leverage this performance to further expand globally and pursue digital asset investments.
Read more →COSM▼ -12.8%on this news
Cosmos Health Regains Compliance with Nasdaq Minimum Bid Price Requirement CHICAGO, IL / GLOBE NEWSWIRE /
Cosmos Health Inc. has successfully regained compliance with the Nasdaq minimum bid price requirement, as confirmed by a notice received on October 15, 2025. This follows an 18-day period where the company's stock price consistently stayed above the required $1.00 per share. CEO Greg Siokas expressed satisfaction with this achievement, emphasizing the organic growth stemming from the company's strategic initiatives. Cosmos Health continues to focus on enhancing shareholder value through innovation and operational excellence in its diverse healthcare offerings.
Read more →COSMCosmos Health CEO Issues Letter to Shareholders: Building a Global Healthcare Powerhouse with $300M Digital Financing Facility, U.S. Manufacturing Expansion, and AI Innovation CHICAGO, IL / GLOBE NEWSWIRE /
Cosmos Health CEO Greg Siokas issued a letter to shareholders highlighting strategic advancements toward building a globally integrated healthcare powerhouse. The company secured a $300 million digital financing facility to enhance operational capabilities and drive innovation in areas including U.S. manufacturing and AI. Their comprehensive growth strategy aims to expand brand recognition and create a robust therapeutics pipeline while integrating modern technologies in healthcare delivery. With significant investments positioned for expansion, Cosmos Health is focused on navigating market challenges and delivering shareholder value.
Read more →COSM▲ +31%on this news
Cosmos Health Secures up to $300 Million Financing Facility to Launch Ethereum Treasury Strategy CHICAGO, IL / GLOBE NEWSWIRE /
Cosmos Health Inc. has announced a financing agreement for up to $300 million to launch its Ethereum treasury strategy, aimed at enhancing shareholder value. This initiative will involve the strategic accumulation and staking of ETH assets through institutional infrastructure. The financing is part of the company's broader digital transformation and plans for U.S. manufacturing. The CEO emphasized that the company's entry into the digital asset space is a long-term commitment rather than a short-term pivot.
Read more →COSMCosmos Health Receives Additional 180-Day Compliance Period from Nasdaq CHICAGO, IL / ACCESSWIRE /
Cosmos Health Inc. has been granted an additional 180-day period by Nasdaq to comply with the $1.00 minimum bid price requirement. Previously notified of non-compliance after the bid price fell below this threshold for 30 days, the company is focused on regaining compliance within the new timeframe. The CEO has expressed confidence in meeting the necessary requirements to avoid delisting and appreciates Nasdaq's continued support during this process.
Read more →COSMCosmos Health Announces It Will Not Proceed with an Offering Under Its Form S-1 CHICAGO, IL / ACCESSWIRE /
Cosmos Health Inc. has announced that it will not proceed with its planned offering under Form S-1 until after filing its Annual Report on Form 10-K for the fiscal year ending December 31, 2024. This decision raises concerns regarding the company's financial stability and operational strategy moving forward. Additionally, the delay in the offering may impact investor sentiment and the company's ability to raise capital in the future.
Read more →COSMCosmos Health Regains Compliance with Nasdaq Minimum Bid Price Rule CHICAGO, IL / ACCESSWIRE /
Cosmos Health Inc. has announced that it has regained compliance with the Nasdaq minimum bid price requirement, achieving a closing bid price of $1.00 per share over ten consecutive business days. This compliance return was confirmed in a notification letter from Nasdaq. The company's CEO, Greg Siokas, expressed satisfaction with this outcome, noting that it was achieved without the need for a reverse stock split. This development keeps Cosmos Health listed on Nasdaq, allowing for continued operations and growth opportunities.
Read more →COSMCosmos Health Receives Additional Delinquency Letter from Nasdaq Regarding Late Filings of Its Forms 10-K and 10-Q CHICAGO, IL / ACCESSWIRE /
Cosmos Health Inc. received an additional delinquency letter from Nasdaq due to its failure to file required documentation on time. The company remains out of compliance with Nasdaq's listing requirements, specifically for its Form 10-Q and Form 10-K filings. Although there is a plan in place for compliance, there are concerns about potential consequences if Nasdaq does not approve the plan. The company reports it will submit this plan by the required deadline.
Read more →COSM▼ -20.4%on this news
Cosmos Health Receives Nasdaq Notice on Late Filing of Its Form 10-K CHICAGO, IL / ACCESSWIRE /
Cosmos Health Inc. has received a notification from Nasdaq due to its failure to file the Annual Report on Form 10-K for the period ended December 31, 2023. This status puts the company in non-compliance with Nasdaq Listing Rule 5250(c)(1), though there is no immediate impact on its stock listing. The company has 60 days to submit a plan to regain compliance, with a possible extension of up to 180 days if accepted. CEO Greg Siokas stated that the team is working diligently to resolve the issue.
Read more →COSMRELATED PARTY TRANSACTION POLICIES AND PROCEDURES POLICY It is the policy of the Board of Directors ("Board") of Cosmos Health Inc. ("Company") that all Related Party Transactions, as that term is defined in this policy
Cosmos Health Inc. has implemented formal policies and procedures regarding Related Party Transactions to ensure transparency and governance. The Board of Directors has assigned the Audit Committee to review these transactions, allowing for pre-approval in certain cases. This policy requires thorough documentation and consideration of the transaction terms to ensure they are comparable to those offered to third parties. The Company may make recommendations for the creation of special committees if necessary.
Read more →COSMCosmos Health Bolsters Presence in $400Bn+ Global Generic Drugs Market with $3.5M Acquisition of 10-Drug Portfolio CHICAGO, IL / ACCESSWIRE /
Cosmos Health has announced the acquisition of a 10-drug portfolio from a related party for approximately $3.5 million, bolstering its presence in the global generic drugs market valued at over $400 billion. The drugs selected for this portfolio address various health issues, including diabetes and heart conditions. This strategic move aims to enhance Cosmos Health's pharmaceutical offerings and expands its in-house manufacturing capabilities through its subsidiary, Cana Laboratories. The CEO expressed optimism about diversifying the company's revenue streams and capturing a larger share of the growing generic drug market.
Read more →COSM▲ +10.1%on this news
Cosmos Health Set for Substantial Growth From Acquisitions Completed in 2023 In 2023, Cosmos Health concluded multiple acquisitions, including Cana Laboratories, the distribution network owned by Bikas GP, and ZipDoctor.
Cosmos Health has concluded multiple acquisitions in 2023, including Cana Laboratories, Bikas GP's distribution network, and ZipDoctor. These acquisitions are anticipated to significantly boost revenues, projecting nearly $4 million in FY 2023 and over $12.5 million in FY 2024. The company plans to enhance production capacity and invest in further growth, particularly with its key acquisition, Cana Laboratories. With no debt and a strong financial outlook, Cosmos Health aims to integrate and leverage its new assets effectively.
Read more →COSM▼ -6.4%on this news
Cosmos Health Reports Q3 2023 Results; Revenue Increased 7% YoY, Total Assets Reached Record $71.5M with Stockholders' Equity of $44.2M or $3.4/Share THESSALONIKI, GREECE / ACCESSWIRE /
Cosmos Health Inc. reported a 7% increase in revenue for Q3 2023, reaching $12.8 million, attributed to its logistics distribution expansion. Despite the growth, gross margins fell to 9.5% due to a larger contribution from lower-margin segments. SG&A costs surged to $4.0 million, reflecting elevated R&D and acquisition costs. The company also indicated plans for substantial growth, expecting to surpass $180 million in revenue by 2026 and initiated a stock buyback program to stabilize its stock price.
Read more →COSMCOSMOS HEALTH CEO Issues Letter to Shareholders Company reaches major strategic inflection point, with operations and revenue ramp-up underway, to significantly accelerate in 2024 and beyond Maintains solid balance sheet
Cosmos Health Inc. has reached a strategic inflection point, with CEO Greg Siokas reporting substantial progress in operations and revenue growth. The company successfully completed three acquisitions in 2023 and aims to achieve over $180M in gross annual revenue by 2026. With a solid balance sheet featuring negligible debt and strong assets, Cosmos Health is also seeing success in expanding its nutraceutical brands globally. The CEO has heavily invested in the company, demonstrating commitment to its future growth.
Read more →COSM▲ +34.3%on this news
Cosmos Health Introduces Guidance; Expects to Achieve Over $180M in Gross Annual Revenue and EBITDA in Excess of $20M by 2026; Recaps Significant Events Reported So Far in 2023 Company reaches major strategic inflection
Cosmos Health Inc. has introduced its inaugural guidance for 2026, projecting over $180 million in gross annual revenue and an EBITDA exceeding $20 million. The company has reported significant operational milestones throughout 2023, including three acquisitions and advancements in research and development. With a strong balance sheet and strategic plans to enhance shareholder value, Cosmos Health aims to capitalize on its growth potential through vertical integration and expanding product lines. CEO Greg Siokas emphasized a focused approach to execution, balancing growth with sustainability as they move forward.
Read more →COSMCosmos Health Reports Q2 2023 Financial Results; Adjusted Net Income Increases by 3550% to Surpass $3 Million for H1 2023 vs $(0.09) Million H1 2022; Book Value per Share Exceeds $4.04 CHICAGO, IL /
Cosmos Health reported significant financial improvements in Q2 2023, with an adjusted net income increase of 3550% compared to the previous year. Though revenues declined slightly due to adverse exchange rates, the company nonetheless achieved positive adjusted EBITDA and completed transformative acquisitions expected to enhance future revenues. Financial metrics like book value per share and stockholders' equity also showed strong growth. The company's diversified approach and focus on innovative R&D position it for continued success.
Read more →COSM▼ -23.4%on this news
Cosmos Health Inc. Announces Pricing of $5.25 Million Registered Direct Offering and Concurrent Private Placement CHICAGO, IL / ACCESSWIRE /
Cosmos Health Inc. has announced a registered direct offering and concurrent private placement worth approximately $5.25 million, involving the sale of over 2 million shares of common stock. The proceeds are intended for working capital and general corporate purposes, and the transaction is expected to close on July 21, 2023. Notably, CEO Grigorios Siokas is participating without warrants, showcasing confidence in the company. Furthermore, existing warrants will be amended to lower their exercise price, a move that could suggest volatility in stock valuation.
Read more →COSMCosmos Health Ends 2022 with Transformed Balance Sheet and Achieves Positive Adjusted EBITDA for the Fiscal Year 2022 CHICAGO, IL / ACCESSWIRE /
Cosmos Health Inc. reported its financial results for the fiscal year 2022, ending with a positive adjusted EBITDA of $0.5 million despite a revenue decline to $50.3 million due to currency variations. The company significantly improved its balance sheet, reducing long-term debt by 76% and achieving a cash position of approximately $21 million. Management highlighted ongoing growth initiatives, including acquisitions that could enhance their product portfolio and market presence. While challenges such as net losses were noted, the company is focusing on future expansion within the healthcare sector.
Read more →COSMCosmos Health Announces the Appointment of Nikos Bardakis, an Experienced Executive in the Pharmaceutical Industry, as Chief Operating Officer CHICAGO, IL / ACCESSWIRE /
Cosmos Health has appointed Nikos Bardakis as Chief Operating Officer, aiming to enhance operational capabilities and facilitate global expansion. Bardakis brings over two decades of experience in the pharmaceutical sector, previously serving as National Sales Director at Servier Hellas. His predecessor, Pavlos Ignatiades, will transition to Chief Communications Officer to continue enhancing the company’s message and public relations. The company anticipates significant growth and transformation as it repositions from a holding company to a focused health care sector entity.
Read more →COSM▼ -67%on this news
Cosmos Health Inc. Announces Pricing of $32.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market CHICAGO, IL / ACCESSWIRE /
cosm_ex991.htm EXHIBIT 99.1 Cosmos Health Inc. Announces Pricing of $32.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market CHICAGO, IL / ACCESSWIRE / December 19, 2022 / Cosmos Health Inc. (the "Company") (Nasdaq: COSM), a global healthca
Read more →COSM▲ +178.9%on this newsshared move
Cosmos Holdings Inc. Changes its Name to Cosmos Health Inc. and Announces a 1-For-25 Reverse Stock Split CHICAGO
Cosmos Holdings Inc. Changes its Name to Cosmos Health Inc. Announces a 1-For-25 Reverse Stock Split CHICAGO, December 16, 2022 (GLOBE NEWSWIRE) -Cosmos Holdings Inc. d/b/a Cosmos Health ("the Company") (Nasdaq: COSM), a global healthcare group with proprietary lines of nutrace
Read more →COSM▼ -17.6%on this news
Cosmos Health Reports Third Quarter 2022 Financial Results CHICAGO
cosm_ex991.htm EXHIBIT 99.1 Cosmos Health Reports Third Quarter 2022 Financial Results CHICAGO, November 15, 2022 (GLOBE NEWSWIRE) - Cosmos Holdings (d/b/a Cosmos Health, Inc.) ("the Company") (Nasdaq: COSM), a global healthcare group with proprietary lines of nutraceuticals an
Read more →COSM▲ +8.7%on this news· ran to +33% by day 3
Cosmos Health Reports 202.42 % Increase in Adjusted EBITDA and Positive Operating Income for the First Half of 2022 CHICAGO
cosm_ex991.htm EXHIBIT 99.1 Cosmos Health Reports 202.42 % Increase in Adjusted EBITDA and Positive Operating Income for the First Half of 2022 CHICAGO, August 22, 2022 (GLOBE NEWSWIRE) -- Cosmos Health, Inc. ("the Company") (Nasdaq: COSM), a global healthcare group with propr
Read more →COSM▼ -10%on this news
Cosmos Holdings Announces Agreement to Acquire Cana Laboratories, a Legacy European Pharmaceutical Company Established in 1928; Vertically Integrating its Manufacturing and R&D Capabilities and Expanding its Product Pipe
cosm_ex991.htm EXHIBIT 99.1 Cosmos Holdings Announces Agreement to Acquire Cana Laboratories, a Legacy European Pharmaceutical Company Established in 1928;Vertically Integrating its Manufacturing and R&D Capabilities and Expanding its Product Pipeline with New Brands CHICAGO, J
Read more →COSM▲ +11.1%on this news· ran to +27% by day 1
Cosmos Holdings Reports 12.5% Increase in Revenue, 88.9% Increase in Gross Profit and Achieves Profitability for the First Quarter of 2022 Reports positive net income of $0.2 million and $1.2 million of EBITDA for the fi
cosm_ex991.htm EXHIBIT 99.1 Cosmos Holdings Reports 12.5% Increase in Revenue, 88.9% Increase in Gross Profit and Achieves Profitability for the First Quarter of 2022 Reports positive net income of $0.2 million and $1.2 million of EBITDA for the first quarter of 2022 CHICAGO,
Read more →COSMCosmos Holdings Announces Closing of $6 Million Private Placement of Convertible Preferred Stock and Start of Trading on the Nasdaq
cosm_ex991.htm EXHIBIT 99.1 Cosmos Holdings Announces Closing of $6 Million Private Placement of Convertible Preferred Stock and Start of Trading on the Nasdaq February 28, 2022 17:00 ET | Source: Cosmos Holdings CHICAGO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc.
Read more →COSMCosmos Holdings Announces Shareholder Approval of Private Offering Cosmos Holdings
cosm_ex991.htm EXHIBIT 99.1 Cosmos Holdings Announces Shareholder Approval of Private Offering CHICAGO, December 20, 2021 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. ("the Company") (OTCQX: COSM), an international pharmaceutical company with a proprietary line of nutraceuticals a
Read more →COSMPro Forma Balance Sheet as of
PRO FORMA BALANCE SHEET cosm_ex991.htm EXHIBIT 99.1 As 'Adjusted Pro Forma (1) Adjustments September 30, 2021 (Unaudited) (Unaudited) (Unaudited) ASSETS CURRENT ASSETS: Cash and cash equivalents $ 5,683,875 $ 4,650,000 $ 1,033,875 Accounts
Read more →COSMCosmos Holdings Provides First Quarter 2021 Business Update; Reports 89% Year-Over-Year and 60% Sequential Increase in Nutraceutical Business CHICAGO
cosm_ex991.htm EXHIBIT 99.1 Cosmos Holdings Provides First Quarter 2021 Business Update; Reports 89% Year-Over-Year and 60% Sequential Increase in Nutraceutical Business CHICAGO, May 18, 2021 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. ("the Company") (OTCQX: COSM), a vertically
Read more →COSMCosmos Holdings +1 312 536 3102 info@cosmoshold.com 141 West Jackson Blvd., Suite 4236 Chicago, IL 60604 FOR IMMEDIATE RELEASE COSMOS HOLDINGS, INC. REPORTS RECORD THIRD QUARTER AND NINE-MONTH FINANCIAL RESULTS Revenue I
cosm_ex991.htm EXHIBIT 99.1 141 West Jackson Blvd., Suite 4236 COSMOS HOLDINGS, INC. REPORTS RECORD THIRD QUARTER AND NINE-MONTH FINANCIAL RESULTS Revenue Increases 48%, Gross profit increased 210% to $2.39 million and Earnings Rise over Same 2019 Period Generics and Nutrace
Read more →COSMFINANCIAL STATEMENTS Amplerissimo Ltd. (A Development Stage Company) Index to Financial Statements Item Page No. Report of Independent Registered Public Accounting Firm 1 Balance Sheets as of
FINANCIAL STATEMENTS (A Development Stage Company) Index to Financial Statements Item Page No. Report of Independent Registered Public Accounting Firm 1 Balance Sheets as of December 31, 2012 and 2011 3 Statements of Operations for the years ended December 31, 2012 and
Read more →COSMSHARE CONTRIBUTION AGREEMENT This Share Contribution Agreement (the Agreement ) is made and entered into as of the 25 th day of September 2012, between Prime Estates and Developments, Inc., a Nevada corporation ( PMLT )
SHARE CONTRIBUTION AGREEMENT This Share Contribution Agreement (the "Agreement") is made and entered into as of the 25th day of September 2012, between Prime Estates and Developments, Inc., a Nevada corporation ("PMLT") and the shareholders ("Contributors") of Mainline Land Co
Read more →Competitive Position
How COSM ranks across every disease it competes inCompetitive Position is a premium feature
See how COSM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial